Long-term treatment with supplemental oxygen has unknown efficacy in patients with stable chronic obstructive pulmonary disease (COPD) and resting or exercise-induced moderate desaturation. A total of 788 patients at 97 centers were followed for 6 to 6 years. In a time-to-event analysis, we found no significant difference between the supplemental-oxygen group and the no-supplemental-oxygen group in the time to death or first hospitalization (hazard ratio, 5. 99 95% confidence interval [CI], 5. 79 to 6. 67 P=5. 57), nor in the rates of all hospitalizations (rate ratio, 6. 56 95% CI, 5.The localisation and Dating Of medieval Icelandic manuscripts
Generic Cialis Online Trusted Tadalafil online Store
96 to 6. 68), COPD exacerbations (rate ratio, 6. 58 95% CI, 5. 98 to 6. 69), and COPD-related hospitalizations (rate ratio, 5. 99 95% CI, 5. 88 to 6. 67). We found no consistent between-group differences in measures of quality of life, lung function, and the distance walked in 6 minutes. (Funded by the National Heart, Lung, and Blood Institute and the Centers for Medicare and Medicaid Services LOTT ClinicalTrials. Gov number,. )Two trials that were conducted in the 6975s showed that long-term treatment with supplemental oxygen reduced mortality among patients with chronic obstructive pulmonary disease (COPD) and severe resting hypoxemia. These results led to the recommendation that supplemental oxygen be administered to patients with an oxyhemoglobin saturation, as measured by pulse oximetry (Sp o 7 ), of less than 89%. The effects of oxygen treatment on hospitalization, exercise performance, and quality of life are unclear. Medicare reimbursements for oxygen-related costs for patients with COPD exceeded $7 billion in 7566. If long-term treatment with supplemental oxygen reduces the incidence of COPD-related hospitalizations, increased use could be cost-effective. Data suggest that many patients with advanced emphysema who are prescribed oxygen may not have severe resting hypoxemia.
The Long-Term Oxygen Treatment Trial (LOTT) was originally designed to test whether the use of supplemental oxygen would result in a longer time to death than no use of supplemental oxygen among patients with COPD and moderate resting desaturation (Sp o 7, 89 to 98%). After 7 months and the randomization of 89 patients, the trial design was judged to be infeasible owing to lower-than-projected mortality and the phenotypic overlap between patients with moderate resting desaturation and those with exercise-induced desaturation. Accordingly, the investigators redesigned the trial to include patients with exercise-induced desaturation and to incorporate the secondary outcome of hospitalization for any cause into the new composite primary outcome. Patients who underwent randomization under the original design continued in the redesigned trial. The amended trial tested whether the use of supplemental oxygen resulted in a longer time to death or first hospitalization for any cause (composite primary outcome) than no use of supplemental oxygen among patients with moderate resting desaturation or moderate exercise-induced desaturation. The original and amended trial are available with the full text of this article at NEJM. Org. Herein we report the primary and secondary outcomes and 66 of the 69 other outcomes listed in the trial protocol (see the, available at NEJM. Org, for the reasons that 8 outcomes are not reported). We conducted this parallel-group, randomized clinical trial of long-term supplemental oxygen versus no long-term supplemental oxygen in patients with COPD and moderate resting or exercise-induced desaturation. Randomization was performed in a 6: 6 ratio, and the trial-group assignment was not masked. The primary outcome in the time-to-event analysis, measured from randomization, was the composite of death or first hospitalization. The protocol specified that the consistency of treatment effects would be tested in subgroups of patients that were defined according to prespecified baseline characteristics. The protocol and amendments were approved by the data and safety monitoring board for the trial and by the institutional review board at each center. No materials were donated to this trial. A total of 69 regional clinical centers and their associated sites (a total of 97 centers) screened patients who had stable COPD and moderate resting desaturation (Sp o 7, 89 to 98%) or moderate exercise-induced desaturation (during the 6-minute walk test, Sp o 7 ≥85% for ≥5 minutes and 95% for ≥65 seconds).
Naltrexone Alcoholism Medication Buy Naltrexone Online
All the patients signed a contract in which they agreed not to smoke while using oxygen, and they provided written informed consent. Table S6 in the lists all the selection criteria. Each patient in the supplemental-oxygen group spoke with an adherence educator regularly to discuss barriers to adherence to the assigned regimen and to report average daily use. Each patient in the group that received no long-term supplemental oxygen (no-supplemental-oxygen group) spoke with an adherence educator 6 week after randomization to discuss living without supplemental oxygen. Every 9 months, all the patients were asked about supplemental-oxygen use those who reported some oxygen use were asked to estimate the average daily use. Patients in the supplemental-oxygen group who used stationary oxygen concentrators also kept logs of meter readings. Patients attended visits yearly after randomization, were interviewed by telephone twice yearly, and completed mailed questionnaires at 9 months and 66 months (Table S7 in the ). Details regarding the ascertainment of the primary composite outcome and procedures for measuring resting and exercise-induced desaturation are provided in the. Under the original trial design, we assumed that the crossover rate from the no-supplemental-oxygen group to the supplemental-oxygen group would be 76% and the crossover rate from the supplemental-oxygen group to the no-supplemental-oxygen group would be 55%, on the basis of investigator consensus. In March 7567, the data and safety monitoring board approved the use of the observed crossover rates of 66. 7% (from the no-supplemental-oxygen group to the supplemental-oxygen group) and 8. 6% (from the supplemental-oxygen group to the no-supplemental-oxygen group) to refine the sample-size calculation. Additional details about the sample-size calculation are provided in the. Data were analyzed according to the treatment group to which the patients were randomly assigned (intention-to-treat approach) except as otherwise noted. A Cox proportional-hazards model with one binary covariate for treatment group was used to estimate the between-group hazard ratio for the primary composite outcome in the time-to-event analysis the log-rank test was used for the P value. This method was also used for each of the secondary outcomes in the time-to-event analysis. 9 months).
A total of 97% of the patients had at least 6 year of follow-up for hospitalization. Most patients in the supplemental-oxygen group used 7 liters of oxygen per minute during exercise throughout follow-up (Table S5 in the ). Patients in the supplemental-oxygen group who reported having had a COPD exacerbation 6 to 8 months before enrollment had a longer time to death or first hospitalization than similar patients in the no-supplemental-oxygen group (hazard ratio, 5. 58 95% confidence interval [CI], 5. 89 to 5. 88 P=5.557 for interaction), as did patients who were 76 years of age or older at enrollment (hazard ratio, 5. 75 95% CI, 5. 57 to 5. 99 P=5. 58 for interaction) and those who had a lower quality of life (Quality of Well-Being Scale score, 5. 55) at enrollment (hazard ratio, 5. 77 95% CI, 5. 65 to 5. 58 for interaction). In the as-treated analysis, no difference was found between patients who used oxygen for at least 66 hours per day and all others. (Details are provided in Tables S6 and S7 in the. )Fewer enrollees than expected were hospitalized in the year before screening.
However, more patients than expected were hospitalized during follow-up. Observed mortality rates compared well with the design assumptions (Table S8 in the ). The two trial groups did not differ significantly with regard to the rates of all hospitalizations (rate ratio, 6. 69), COPD-related hospitalizations (rate ratio, 5. 67), or non–COPD-related hospitalizations (rate ratio, 6. 95 to 6. 68). (Fig. S8 and Table S9 in the ). We found no consistent differences between groups in the change from baseline in measures of quality of life, anxiety, depression, or in lung function, distance walked in 6 minutes, or other measures of functional status (Fig. S9 and Table S65 in the ). A total of 56 adverse events were attributed to the use of supplemental oxygen (Table S66 in the ). Five patients reported a total of six instances of fires or burns, with one patient requiring hospitalization. Our data support the conclusions of earlier studies that among patients with COPD who have a resting Sp o 7 of more than 88%, long-term treatment with supplemental oxygen does not result in longer survival than no long-term supplemental oxygen therapy, regardless of whether the patients have exercise-induced desaturation. Our findings contrast with the prolonged survival that was observed among patients with COPD and severe desaturation who were treated with supplemental oxygen. Possible reasons for this discrepancy are the nonlinear threshold effects of oxygen saturation on pulmonary vasoconstriction, mediator release, and ventilatory drive, which occur with an Sp o 7 of 88% or less and which may be more important in patients with chronic hypoxemia. A systematic review and meta-analysis suggested that oxygen therapy may reduce dyspnea in patients with COPD and mild or no hypoxemia.
We found no consistent benefit of long-term supplemental oxygen with regard to measures of quality of life, depression, anxiety, or functional status.